prikaz prve stranice dokumenta Javnozdravstveni problem rezistencije bakterije Helicobacter pylori
  Download
PDF 255.37 KB
Professional paper - Professional paper
Javnozdravstveni problem rezistencije bakterije Helicobacter pylori
Medica Jadertina, 46 (2016), 1-2; 25-30. urn:nbn:hr:184:887540
Bešlić, Ivan; Baturina, Stjepan; Mihalj, Monika; Zekanović, Dražen; Ljubičić, Neven; Turčinov, Jadranko

Cite this document

Bešlić, I., Baturina, S., Mihalj, M., Zekanović, D., Ljubičić, N. & Turčinov, J. (2016). Javnozdravstveni problem rezistencije bakterije Helicobacter pylori. Medica Jadertina, 46. (1-2), 25-30. Retrieved from https://urn.nsk.hr/urn:nbn:hr:184:887540

Bešlić, Ivan, et al. "Javnozdravstveni problem rezistencije bakterije Helicobacter pylori." Medica Jadertina, vol. 46, no. 1-2, 2016, pp. 25-30. https://urn.nsk.hr/urn:nbn:hr:184:887540

Bešlić, Ivan, Stjepan Baturina, Monika Mihalj, Dražen Zekanović, Neven Ljubičić and Jadranko Turčinov. "Javnozdravstveni problem rezistencije bakterije Helicobacter pylori." Medica Jadertina 46, no. 1-2 (2016): 25-30. https://urn.nsk.hr/urn:nbn:hr:184:887540

Bešlić, I., et al. (2016) 'Javnozdravstveni problem rezistencije bakterije Helicobacter pylori', Medica Jadertina, 46(1-2), pp. 25-30. Available at: https://urn.nsk.hr/urn:nbn:hr:184:887540 (Accessed 16 November 2024)

Bešlić I, Baturina S, Mihalj M, Zekanović D, Ljubičić N, Turčinov J. Javnozdravstveni problem rezistencije bakterije Helicobacter pylori. Medica Jadertina [Internet]. 2016 [cited 2024 November 16];46(1-2):25-30. Available at: https://urn.nsk.hr/urn:nbn:hr:184:887540

I. Bešlić, S. Baturina, M. Mihalj, D. Zekanović, N. Ljubičić and J. Turčinov, "Javnozdravstveni problem rezistencije bakterije Helicobacter pylori", Medica Jadertina, vol. 46, no. 1-2, pp. 25-30, 2016. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:887540. [Accessed: 16 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (croatian)Javnozdravstveni problem rezistencije bakterije Helicobacter pylori
Title (english)Helicobacter pylori resistance as a public health issue
AuthorIvan Bešlić
AuthorStjepan Baturina
AuthorMonika Mihalj
AuthorDražen Zekanović
AuthorNeven Ljubičić
AuthorJadranko Turčinov
Author's institutionUniversity of Rijeka
Faculty of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Abstract (croatian)
Eradikacija infekcije Helicobacter pylori prvi je korak u liječenju bolesti koje su povezane s ovom infekcijom. U terapijskim protokolima koriste se uobičajeno kombinacije dvaju antibiotika i jednoga lijeka koji suprimira izlučivanje želučane kiseline (inhibitor protonske pumpe – IPP). Kombinacije lijekova podijeljene su u lijekove prve linije, lijekove druge linije i lijekove treće linije, s tim da se u trećoj liniji izbor lijeka zasniva na testiranju osjetljivosti na antibiotik izoliranoga soja H. pylori. Povećana primjena antibiotika dovela je do porasta rezistencije bakterije, te u konačnici do neuspjeha u liječenju. Porast se najviše ogleda u povećanoj rezistenciji na klaritromicin, a novija istraživanja donose podatke o povećanju rezistencije i na levofloksacin. Obzirom da sama bakterija posjeduje izrazitu otpornost na čimbenike okoline, sužen je izbor antibiotika koji bi potencijalno došli u obzir kao lijekovi za eradikaciju. H. pylori je bakterija koja se većim dijelom pojavljuje u nerazvijenim zemljama, u kojima ne postoji učinkovit sustav kontrole nad povećanjem rezistencije. Zbog toga, kao i zbog široke primjene antibiotika uopće, javlja se izazov koji na jednu stranu stavlja eradikaciju infekcije kod zaraženih, a na drugu stranu sve veći postotak rezistencije i samim time neuspješnost liječenja infekcije.
Abstract (english)
Eradication of infection Helicobacter pylori is the first step in curing diseases connected to the infection. The usual combinations of two antibiotics and one drug which suppress the gastric acid secretion (Proton-pump inhibitors – PPI) are used in treatment protocols. Combinations of drugs are divided into first-line drugs, second-line drugs and third-line drugs, taking into account that the choice of drugs in third-line is based on sensibility testing to the antibiotic of isolated strain H. pylori. Increased usage of antibiotics has resulted in greater resistance of the bacteria and finally to failure in treatment. The rise is most evident in increased resistance to clarithromycin, and recent studies show data of increased resistance also to levofloxacin. Considering that the bacteria itself has an extremely high resistance to environmental factors, the choice of antibiotics which could potentially be considered as drugs for eradication is significantly narrowed. H. pylori is a bacterium which is predominant in underdeveloped countries where there is no efficient control system regarding the increase of resistance. Due to that and the wide usage of antibiotics in general, there is a challenge which places eradication of the infection in the already infected patients on one side, and the ever growing resistance which leads to failure of infection treatment on the other side.
Keywords (croatian)
Keywords (english)
Languagecroatian
Languageenglish
Publication typeProfessional paper - Professional paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleMedica Jadertina
Numberingvol. 46, no. 1-2, pp. 25-30
p-ISSN0351-0093
URN:NBNurn:nbn:hr:184:887540
Publication2016
Document URLhttps://hrcak.srce.hr/159833
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2022-01-28 12:30:33